Evidence map›Paper›PMID 37208127›Full record

ArticleJournal of psychiatry & neuroscience : JPN

Genomic variants and inferred biological processes in multiplex families with Tourette syndrome.

Jakub P Fichna, Małgorzata Borczyk, Marcin Piechota, Michał Korostynski, Cezary Zekanowski, Piotr Janik

Open access · diamondAbstract read
In one paragraph

Article in Journal of psychiatry & neuroscience : JPN. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. A Novel Exon Duplication in theThe application of clinical genetics · 2025
    Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Jakub P FichnaFrom the Department of Neurogenetics and Functional Genomics (Fichna, Zekanowski), Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland; the Department of Biological Sciences (Fichna), Purdue University, West Lafayette, Ind., USA; the Laboratory of Pharmacogenomics (Borczyk, Piechota, Korostynski), Department of Molecular Neuropharmacology, Maj Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland; and the Department of Neurology (Janik), Medical University of Warsaw, Warsaw, Poland jfichna@imdik.pan.pl.
Małgorzata BorczykFrom the Department of Neurogenetics and Functional Genomics (Fichna, Zekanowski), Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland; the Department of Biological Sciences (Fichna), Purdue University, West Lafayette, Ind., USA; the Laboratory of Pharmacogenomics (Borczyk, Piechota, Korostynski), Department of Molecular Neuropharmacology, Maj Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland; and the Department of Neurology (Janik), Medical University of Warsaw, Warsaw, Poland.
Marcin PiechotaFrom the Department of Neurogenetics and Functional Genomics (Fichna, Zekanowski), Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland; the Department of Biological Sciences (Fichna), Purdue University, West Lafayette, Ind., USA; the Laboratory of Pharmacogenomics (Borczyk, Piechota, Korostynski), Department of Molecular Neuropharmacology, Maj Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland; and the Department of Neurology (Janik), Medical University of Warsaw, Warsaw, Poland.
Michał KorostynskiFrom the Department of Neurogenetics and Functional Genomics (Fichna, Zekanowski), Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland; the Department of Biological Sciences (Fichna), Purdue University, West Lafayette, Ind., USA; the Laboratory of Pharmacogenomics (Borczyk, Piechota, Korostynski), Department of Molecular Neuropharmacology, Maj Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland; and the Department of Neurology (Janik), Medical University of Warsaw, Warsaw, Poland.
Cezary ZekanowskiFrom the Department of Neurogenetics and Functional Genomics (Fichna, Zekanowski), Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland; the Department of Biological Sciences (Fichna), Purdue University, West Lafayette, Ind., USA; the Laboratory of Pharmacogenomics (Borczyk, Piechota, Korostynski), Department of Molecular Neuropharmacology, Maj Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland; and the Department of Neurology (Janik), Medical University of Warsaw, Warsaw, Poland.
Piotr JanikFrom the Department of Neurogenetics and Functional Genomics (Fichna, Zekanowski), Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland; the Department of Biological Sciences (Fichna), Purdue University, West Lafayette, Ind., USA; the Laboratory of Pharmacogenomics (Borczyk, Piechota, Korostynski), Department of Molecular Neuropharmacology, Maj Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland; and the Department of Neurology (Janik), Medical University of Warsaw, Warsaw, Poland.
Medical University of Warsaw · PLMaj Institute of Pharmacology · PLPurdue University West Lafayette · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTourette syndrome is a developmental neuropsychiatric disorder. Its etiology is complex and elusive, although an important role of genetic factors has been established. The aim of the present study was to identify the genomic basis of Tourette syndrome in a group of families with affected members in 2 or 3 generations.

methodsWhole-genome sequencing was performed followed by co-segregation and bioinformatic analyses. Identified variants were used to select candidate genes, which were then subjected to gene ontology and pathway enrichment analysis.

resultsThe study group included 17 families comprising 80 patients with Tourette syndrome and 44 healthy family members. Co-segregation analysis and subsequent prioritization of variants pinpointed 37 rare and possibly pathogenic variants shared among affected individuals within a single family. Three such variants, in the LIMITATIONS: We did not examine intergenic variants, but they still could influence clinical phenotype.

conclusionOur results provide a further argument for a role of adhesion molecules and synaptic transmission in neuropsychiatric diseases. Moreover, an involvement of processes related to oxidative stress response and sound-sensing in the pathology of Tourette syndrome seems likely.

Indexed as

Tourette SyndromeAldehyde Dehydrogenase, MitochondrialBrainGenomicsHumansPhenotypeSynaptic TransmissionAldehyde Dehydrogenase, MitochondrialALDH2 protein, human

Identifiers

PMID37208127
PMCPMC10205823
OpenAlexW4377092333

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.